These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 14585168)

  • 21. Molecular changes associated with prostate cancer development.
    Ruijter E; Montironi R; van de Kaa C; Schalken J
    Anal Quant Cytol Histol; 2001 Feb; 23(1):67-88. PubMed ID: 11233745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromoplexy: a new paradigm in genome remodeling and evolution.
    Wang K; Wang Y; Collins CC
    Asian J Androl; 2013 Nov; 15(6):711-2. PubMed ID: 23974363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumor heterogeneity in prostate cancer.
    Yadav SS; Stockert JA; Hackert V; Yadav KK; Tewari AK
    Urol Oncol; 2018 Aug; 36(8):349-360. PubMed ID: 29887240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular biology of prostate-cancer pathogenesis.
    Shand RL; Gelmann EP
    Curr Opin Urol; 2006 May; 16(3):123-31. PubMed ID: 16679847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
    Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
    Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prostate cancer: cytogenetic and molecular biology principles].
    Strohmeyer T; Effert P
    Med Klin (Munich); 1993 Aug; 88(8):482-4. PubMed ID: 8413050
    [No Abstract]   [Full Text] [Related]  

  • 27. [ETIOLOGY OF PROSTATE CANCER].
    Altarac S; Galić J; Vidas Ž; Savić I; Štajcar D; Rajković Z; Arslani N; Vučemilo L; Bubnjar J; Papeš D
    Acta Med Croatica; 2015; 69(5):459-65. PubMed ID: 29087091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
    Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
    Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer.
    Hornstein M; Hoffmann MJ; Alexa A; Yamanaka M; Müller M; Jung V; Rahnenführer J; Schulz WA
    Cancer Genomics Proteomics; 2008; 5(2):123-36. PubMed ID: 18460741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes.
    Williams KA; Lee M; Hu Y; Andreas J; Patel SJ; Zhang S; Chines P; Elkahloun A; Chandrasekharappa S; Gutkind JS; Molinolo AA; Crawford NP
    PLoS Genet; 2014 Nov; 10(11):e1004809. PubMed ID: 25411967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.
    Tamura K; Furihata M; Chung SY; Uemura M; Yoshioka H; Iiyama T; Ashida S; Nasu Y; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
    Cancer Sci; 2009 May; 100(5):914-9. PubMed ID: 19298603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.
    Liu W
    Asian J Androl; 2016; 18(4):533-42. PubMed ID: 26975494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcriptional network of androgen receptor in prostate cancer progression.
    Takayama K; Inoue S
    Int J Urol; 2013 Aug; 20(8):756-68. PubMed ID: 23600948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrative biology of prostate cancer progression.
    Tomlins SA; Rubin MA; Chinnaiyan AM
    Annu Rev Pathol; 2006; 1():243-71. PubMed ID: 18039115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
    Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z
    Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical variability and molecular heterogeneity in prostate cancer.
    Shoag J; Barbieri CE
    Asian J Androl; 2016; 18(4):543-8. PubMed ID: 27080479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
    Bussemakers MJ; van Bokhoven A; Verhaegh GW; Smit FP; Karthaus HF; Schalken JA; Debruyne FM; Ru N; Isaacs WB
    Cancer Res; 1999 Dec; 59(23):5975-9. PubMed ID: 10606244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular genetics of prostate cancer.
    Visakorpi T
    Ann Chir Gynaecol; 1999; 88(1):11-6. PubMed ID: 10230676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying molecular features for prostate cancer with Gleason 7 based on microarray gene expression profiles.
    Bălăcescu L; Bălăcescu O; Crişan N; Fetica B; Petruţ B; Bungărdean C; Rus M; Tudoran O; Meurice G; Irimie A; Dragoş N; Berindan-Neagoe I
    Rom J Morphol Embryol; 2011; 52(4):1195-202. PubMed ID: 22203922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.